Pharmaceutical & Life Sciences Safety Staffing

BCSP-Credentialed Pharmaceutical & Life Sciences Safety Staffing

3P Safety Staffing places safety professionals in 48 hours or less. We staff pharmaceutical manufacturing, biotechnology, and contract development and manufacturing organization (CDMO) sites. We also cover gene therapy, cell therapy, sterile injectable, and life sciences research facilities.

Pharma and life sciences run a distinct compliance stack. Each framework governs a different risk:

• cGMP (Current Good Manufacturing Practice) governs product quality and overlaps with EHS programs.
• USP 800 governs hazardous drug handling.
• BSL-1 through BSL-4 biosafety levels govern biological research.
• OSHA 1910.1450 governs laboratory chemical exposure.
• DEA Schedules I-V govern controlled substance handling.
• EPA pharmaceutical hazardous waste rules govern disposal.

Every pharma and life sciences candidate carries at least one BCSP credential plus OSHA 30 General Industry. The specialty bench adds more:

• CIH for industrial hygiene exposure assessment.
• Biosafety officer (RBP) credentials for BSL-2/3 work.
• USP 800 trainer endorsement for hazardous drug compounding scope.
• DEA-controlled-substance security training for facilities with Schedule II/III work.

Founder Patrick Salazar has been in safety since 2005 — NCCCO Mobile/Tower/Inspector/Lift Director, OSHA 500, BCSP member. Pharma and life sciences combine cGMP overlay, controlled environments, and biosafety levels on top of OSHA baseline. Add USP 800 hazardous drug handling and DEA controlled substance regulations. Every candidate is vetted against your specific facility profile.

Our placement history spans the industry:

• Pharmaceutical manufacturers in NJ/PR/NC/IN/MA.
• Biotech firms in MA/CA/MD.
• Sterile injectable fill-finish at multiple sites.
• Gene therapy and cell therapy facilities in MA/CA/PA.
• CDMO operations across the Northeast.
• Life sciences research operations at major university hospitals and research institutes.

Pharmaceutical & Life Sciences Facility Categories We Cover

Below are the facility types where dedicated safety coverage is most often the right call.

• Small molecule pharmaceutical manufacturing — API synthesis, formulation, oral solid dose, oral liquid, topical. Reactor scope, solvent handling, hazardous waste pharma, chemical exposure programs.
• Biologics manufacturing — monoclonal antibody, recombinant protein, vaccine production. Bioreactor operations, harvest and purification, BSL-1 and BSL-2 facilities.
• Sterile injectable fill-finish — pre-filled syringe, vial fill, lyophilized product, large-volume parenteral. Aseptic environment, isolator operations, controlled environment certification.
• Cell therapy and gene therapy manufacturing — autologous and allogeneic cell therapy, lentiviral vector, AAV vector. BSL-2 enhanced facilities, biosafety officer required, USP 800 hazardous drug overlap.
• Pharmaceutical research and development — R&D laboratories, pilot plants, scale-up operations. OSHA 1910.1450 lab standard, chemical hygiene plan.
• Clinical trial materials manufacturing — investigational product, blinded packaging, controlled distribution. cGMP-light environment with future commercial-scale transition.
• Contract development and manufacturing organization (CDMO) — multi-client facilities with cleaning validation between campaigns. Varied product types and a customer audit cycle.
• API and intermediates manufacturing — bulk pharmaceutical chemicals, intermediates, high-potency API (HPAPI). HPAPI containment, OEB (Occupational Exposure Band) Level 4-5 protocols.
• Medical device manufacturing — sterilization (EO, gamma, e-beam), packaging, assembly. ISO 13485 quality system overlap with EHS.
• Diagnostic manufacturing — IVD (in vitro diagnostic) manufacturing, reagent production, instrument assembly.
• Life sciences research facilities — academic medical center research, government research labs (NIH, CDC, USDA), private research institutes.
• Vivarium and animal research — IACUC oversight, animal allergen exposure, occupational health surveillance, BSL-2 ABSL-2 facilities.

Pharma & Life Sciences Customers We Serve

Below is the customer profile driving demand on our pharma and life sciences bench.

• Large pharmaceutical manufacturers — Pfizer, Merck, Johnson & Johnson, AbbVie, Bristol-Myers Squibb, Eli Lilly, Novartis, AstraZeneca, Sanofi, GlaxoSmithKline operations.
• Biotechnology firms — Amgen, Genentech, Biogen, Vertex, Regeneron, Moderna, BioNTech, and venture-backed biotech in MA, CA, NC, MD.
• Sterile injectable CDMOs — Catalent, Lonza, Patheon (Thermo Fisher), Pfizer CentreOne, AGC Biologics, KBI Biopharma.
• Cell and gene therapy operators — Cellectis, bluebird bio, BioMarin, Sarepta Therapeutics, Spark Therapeutics, Solid Biosciences.
• Medical device manufacturers — Medtronic, Boston Scientific, Stryker, Abbott, Edwards Lifesciences operations.
• Diagnostic manufacturers — Abbott Diagnostics, Roche Diagnostics, BD, Beckman Coulter, Hologic, Thermo Fisher Scientific.
• Academic medical center research — Harvard, MIT, Penn, JHU, Duke, Stanford, UCSF research operations.
• Government research laboratories — NIH Bethesda campus, CDC Atlanta and Fort Collins, USDA ARS, FDA labs.
• Private research institutes — Broad Institute, Whitehead, Salk Institute, Scripps Research.
• Pharma construction and renovation contractors — IPS, Burns & McDonnell pharma, Skanska pharma, large pharma-experienced GCs.
• Pharma EPC firms — Jacobs, Fluor, AECOM pharma practices, IPS Mechanical, CRB Engineering.
• Pharma startup and scale-up firms — venture-backed biotech, gene therapy, cell therapy startups moving from R&D to GMP manufacturing.

Pharma & Life Sciences Hazards & Compliance Pressure Points

The hazard inventory below is what pharma-experienced safety candidates need fluency in. The stack overlays OSHA baseline with multiple agency-specific frameworks.

• cGMP (Current Good Manufacturing Practice) — FDA 21 CFR 210, 211, 600. Quality system overlap with EHS programs and deviation investigation overlap with incident investigation. Change control overlap with management of change.
• USP 800 hazardous drug handling — closed-system transfer devices, negative-pressure compounding areas, and PPE selection (chemo gloves, chemo gowns). Spill response and environmental monitoring for hazardous drug surface contamination.
• OSHA 1910.1450 laboratory standard — chemical hygiene plan, chemical hygiene officer designation, and hazard determination. Control measures, training, medical consultation and examination.
• OSHA 1910.1030 bloodborne pathogens — exposure control plan, engineering and work practice controls, and PPE. Training, medical surveillance, hepatitis B vaccination.
• BSL-1 through BSL-4 biosafety levels — CDC/NIH Biosafety in Microbiological and Biomedical Laboratories (BMBL). Engineering controls, work practices, PPE, training escalate with biosafety level.
• USDA APHIS animal research oversight — for vivarium operations; AAALAC accreditation, IACUC protocols, occupational health for animal worker.
• DEA Schedule I-V controlled substances — 21 CFR 1300-1321. Physical security requirements, DEA Form 222 for Schedule I/II, biennial inventory, suspicious order monitoring.
• EPA hazardous waste pharmaceutical (40 CFR 266 Subpart P) — Management Standards for Hazardous Waste Pharmaceuticals. Specific to healthcare and pharmaceutical generators.
• HPAPI containment — Occupational Exposure Band (OEB) Level 4-5 protocols for high-potency API. Closed-system handling, isolator operations, exposure monitoring.
• Ergonomics in clean rooms — extended gowning periods, gloving, repetitive aseptic technique, microscope work in QC labs.
• Chemical exposure — solvents (methanol, acetonitrile, DMSO, THF), reactive intermediates, sensitizers (penicillins, cephalosporins).
• EO sterilization — ethylene oxide exposure in medical device sterilization; 1910.1047 standard, aeration requirements, area and personal monitoring.
• Cleaning validation chemicals — alkaline and acid cleaners, peracetic acid, hydrogen peroxide vapor, sodium hypochlorite, residual cleaning agent monitoring.
• Construction-phase complications — building or renovating cleanrooms with operating adjacent suites. Particulate control and vibration during construction next to fill operations.

Pharma & Life Sciences Regulatory Frameworks

The framework inventory below is what placed candidates work against on a daily basis.

• FDA 21 CFR 210/211 cGMP — primary pharma quality system regulation. Overlaps with EHS at deviation investigation, change control, training documentation.
• FDA 21 CFR 600 Biologics — biologics-specific GMP requirements.
• FDA 21 CFR 820 Quality System Regulation (medical devices) — medical device quality system. Overlaps with EHS at corrective and preventive action (CAPA).
• USP 800 hazardous drugs — handling of hazardous drugs in healthcare settings; pharmacy compounding and manufacturing scope.
• OSHA 1910.1450 lab standard — laboratory chemical exposure; chemical hygiene plan, chemical hygiene officer.
• OSHA 1910.1030 bloodborne pathogens — biological hazard exposure in healthcare and research.
• OSHA 1910.1047 ethylene oxide — for medical device EO sterilization.
• CDC/NIH BMBL — Biosafety in Microbiological and Biomedical Laboratories; defines BSL-1 through BSL-4.
• NIH Office of Biotechnology Activities — recombinant DNA work, IBC (Institutional Biosafety Committee) protocols.
• USDA APHIS — animal research and vivarium operations.
• DEA — controlled substance security, manufacturing quotas, distribution tracking.
• EPA RCRA — hazardous waste generator status, with 40 CFR 266 Subpart P pharma-specific overlay.
• DOT — for facilities shipping clinical samples (Category A or B infectious substances), controlled substances, hazardous waste.
• NRC and state radiation control — for facilities with radiopharmaceuticals or radioactive research materials.
• ISO 14644 cleanroom standards — particulate and microbial control in controlled environments.
• ISO 13485 (medical devices) / ISO 14001 / 45001 — voluntary management system standards.

Pharma Placement Process — Intake to Mobilization

Pharma intake runs deeper than commercial industrial because the role bridges OSHA, FDA cGMP, biosafety, and DEA scope. Most engagements require facility-specific orientation before any productive day on the floor.

• Step 1 — Discovery call (45-60 minutes). We map your facility type — small molecule API, biologics, sterile fill, cell therapy, R&D, medical device, or CDMO. We log product portfolio (small molecule vs biologic vs ATMP) and BSL level. We note USP 800 hazardous drug scope and DEA Schedule status. We also confirm expected work scope (operations, construction, validation, audit prep) and duration. Then the customer audit cycle (FDA, EMA, customer) and shift schedule.
• Step 2 — Roster match (within 24-48 hours). Narrow by pharma vertical and product type. Biologics candidates do not staff into API synthesis without documented cross-experience. Sterile fill candidates do not staff into BSL-3 without biosafety credentials.
• Step 3 — Proposal package. You get a resume with documented pharma project history, BCSP credentials, and OSHA 30 GI. It lists pharma-specific training (USP 800, biosafety, DEA security) and prior facility references with named former supervisors. It also shows FDA inspection history with that candidate (if any) and the all-inclusive rate.
• Step 4 — Multi-stakeholder interview. Plant manager, quality director (cGMP overlap), corporate EHS, biosafety officer if applicable. Pharma placements often involve 3-4 stakeholders on the interview.
• Step 5 — Plant orientation, gowning, GMP training. Plant badging, gowning qualification (sterile facilities require multiple practice gowns), and GMP introduction training. Then deviation reporting system access and EHS management system access (Veeva QualityOne, MasterControl, ETQ Reliance, TrackWise).
• Step 6 — Day-one mobilization. The candidate arrives, completes facility orientation, and reviews open deviations and CAPAs. They walk the suite with operations and quality, then review recent FDA inspection observations if any. Day one is recon; day three is operating.

Standard timing: 24-48 hour proposal, 5-10 day mobilization typical (gowning qualification is the bottleneck for sterile facilities). FDA-regulated facility with significant cGMP overlap can run 10-14 days for full operational readiness.

Cost of Pharma & Life Sciences Safety Staffing

Pharma rates run above standard industrial because the credential stack overlays cGMP, biosafety, USP 800, and DEA scope.

• Mid-tier pharma safety pro (5-10 years, ASP, single-facility experience): $105-$140 per hour all-inclusive.
• Senior pharma safety manager (10+ years, CSP, multi-product facility experience): $135-$175 per hour.
• CIH-credentialed for IH-heavy scope (HPAPI, sensitizer exposure, sterilant): $155-$205 per hour.
• Biosafety officer (RBP-credentialed) for BSL-2/3 facilities: $145-$195 per hour.
• Sterile injectable specialty (aseptic environment, gowning trainer): $135-$180 per hour.
• Cell and gene therapy specialty (autologous/allogeneic manufacturing experience): $145-$195 per hour.
• Pharma construction safety (new build or renovation in operating facility): $130-$170 per hour.
• FDA inspection response specialist (prior 483 response and warning letter remediation): $165-$220 per hour.

All-inclusive covers:

• Payroll, workers comp, and GL
• Mileage within 75 miles of home base
• Weekly safety report
• Standard PPE, including cleanroom-compatible safety footwear

Add-ons cost extra: per diem beyond 75 miles and specialty PPE. Specialty PPE includes chemo gowns and gloves for USP 800, half-face APR or PAPR for HPAPI, and BSL-3 PPE. We also add customer-specific training, such as sponsor company orientations and customer audit prep training.

Engagements typically run 6-30 months at large pharma and 3-18 months at CDMO. Cell and gene therapy operations run 12-36 months during scale-up.

No long-term contract. Conversion to permanent runs 25% of first-year base for pharma — higher than commercial industrial because recruiting is harder. The fee is waived after 6 months of contract billing.

Pharma & Life Sciences Credentials & Specialty Training

The credential roster we vet against per pharma placement.

• BCSP credentials — CSP, ASP, CHST. Senior pharma roles typically require CSP.
• OSHA Outreach — 30-hour General Industry baseline, 510 trainer endorsement, 511 OSHA standards trainer.
• ABIH CIH — Certified Industrial Hygienist for HPAPI, sensitizer exposure, sterilant exposure, EO monitoring scope.
• NEHA / IHMM — CHMM for hazardous waste pharma, CHSP for pharma security.
• Registered Biosafety Professional (RBP) — ABSA-credentialed biosafety officer for BSL-2 enhanced and BSL-3 facilities.
• Certified Biological Safety Professional (CBSP) — senior biosafety officer credential.
• USP 800 trainer — for facilities compounding or manufacturing hazardous drugs.
• Bloodborne pathogens trainer — 1910.1030 annual refresher delivery.
• DEA security training — for facilities with Schedule II/III controlled substance operations.
• HAZWOPER 24/40 — for pharma operations with hazardous waste handling.
• Ethylene oxide trainer — for medical device EO sterilization operations.
• cGMP awareness training — FDA 21 CFR 211, 600, 820 familiarity for EHS-quality overlap.
• Cleanroom gowning qualification — facility-specific practice, monitored by environmental monitoring; multiple successful gowns before independent suite access.
• DOT hazmat shipper — for facilities shipping clinical samples (Category A or B), controlled substances, hazardous waste.
• Combustible dust competent person — for pharma manufacturing with active pharmaceutical ingredient (API) dust hazards.
• First Aid / CPR / AED — current AHA BLS or Red Cross.

Emergency Response, FDA Inspection Surge & Cleanroom Incident Response

Pharma emergencies tend to follow three patterns.

• Scenario 1 — FDA inspection response. FDA pre-approval inspection, surveillance inspection, or for-cause inspection underway. Form 483 observations issued. We mobilize a senior pharma safety pro within 48 hours. They support inspection response, observation triage, CAPA writing, and inspector closeout meeting prep. If inspection escalates to warning letter or consent decree, longer engagement supports the regulatory remediation timeline.
• Scenario 2 — Hazardous drug or biosafety incident. USP 800 spill, BSL-2 enhanced or BSL-3 exposure event, HPAPI containment breach, EO sterilizer release, bloodborne pathogen exposure. We mobilize within 48 hours. Scope: incident investigation, regulatory notification flow, employee medical evaluation coordination, root-cause analysis, and corrective action plan.
• Scenario 3 — Customer audit pre-positioning. Major pharma customer scheduled vendor qualification audit at CDMO. Quality and EHS audit overlap requires program documentation review and gap closure. We deliver 30-90 day prep engagement plus audit-day support.

24/7 dispatch: 252-229-5238. Patrick takes calls for FDA inspection response and biosafety incident response.

Scale-up surge for cell and gene therapy. Cell and gene therapy companies scale from clinical-trial materials to commercial manufacturing. EHS demand concentrates during the 6-18 month scale-up window. We staff added safety bandwidth during scale-up to hold compliance steady as operations get more complex.

Cleanroom construction safety surge. Some pharma facilities build new cleanrooms or renovate suites next to operating production. For those jobs, we provide construction-phase safety coverage. It bridges OSHA construction with cGMP particulate control and operational continuity.

Frequently Asked Questions About Pharmaceutical & Life Sciences Safety Staffing

What pharma and life sciences facility types do you cover?
We cover small molecule pharma manufacturing, biologics (mAbs, recombinant protein, vaccines), and sterile injectable fill-finish. We also staff cell and gene therapy manufacturing (autologous and allogeneic), API and HPAPI manufacturing, medical device, and IVD diagnostics. That includes pharmaceutical R&D and clinical trial materials, plus CDMOs. Also academic medical center research, government research labs (NIH, CDC, USDA), and private research institutes.

Are your safety pros trained on USP 800 hazardous drug handling?
Yes. Pharma sub-roster carries USP 800 training for facilities compounding or manufacturing hazardous drugs. Coverage includes closed-system transfer device protocols, negative-pressure compounding areas, and hazardous drug PPE selection (chemo gloves, chemo gowns). It also covers spill response and environmental monitoring for hazardous drug surface contamination.

Can you handle BSL-2 enhanced and BSL-3 biosafety facilities?
Yes. Biosafety-credentialed sub-roster holds Registered Biosafety Professional (RBP) and Certified Biological Safety Professional (CBSP) credentials through ABSA. Coverage includes BSL-2 enhanced and BSL-3 facility EHS oversight and IBC protocol review. We also handle NIH OBA recombinant DNA work and USDA APHIS animal research oversight. And we apply BMBL-aligned engineering controls and work practices.

Do you provide FDA inspection response support?
Yes. FDA inspection response specialists deliver Form 483 observation triage, CAPA authoring, inspector closeout meeting prep, and remediation timeline coordination. For escalations to warning letter or consent decree, longer engagement supports the regulatory remediation timeline. Rates run $165-$220 per hour for inspection response work.

What does pharma safety staffing cost?
All-inclusive hourly rates run $105-$140 mid-tier and $135-$175 for a senior pharma CSP. CIH scope for HPAPI and sensitizers runs $155-$205, and biosafety RBP for BSL-2/3 runs $145-$195. Sterile injectable specialty runs $135-$180, and cell and gene therapy specialty runs $145-$195. Pharma construction safety runs $130-$170, and FDA inspection response specialist runs $165-$220.

How long does pharma facility orientation and gowning take?
Standard pharma facility orientation runs 5-7 days. Sterile facilities add gowning qualification, extending to 8-10 days. That means multiple successful gowns monitored by environmental monitoring before independent suite access. Cell and gene therapy facilities with USP 800 overlay can extend to 10-14 days. We start orientation paperwork at proposal acceptance to cut total mobilization time.